We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Article |

Antitussives in Jeopardy

William R. Barclay, MD
JAMA. 1973;224(5):621-622. doi:10.1001/jama.1973.03220180041012.
Text Size: A A A
Published online


In the Federal Register, Feb 9, 1973, the Food and Drug Administration (FDA) published a notice to withdraw from the market certain antitussive combinations. Named in the withdrawal notice are the following preparations:

Novrad With ASA

Coricidin With Codeine Phosphate

Phenergan Expectorant With Codeine

Phenergan Expectorant

Phenergan VC Expectorant

Phenergan VC Expectorant With Codeine

Pediatric Phenergan Expectorant

Phenergan Expectorant Troches

Phenergan Expectorant Troches With Codeine

Dimetane Expectorant

Dimetane Expectorant-DC

Omni-Tuss suspension

Tussionex tablets

Ulogesic tablets

Ulominic Syrup

Coditrate Syrup

Methajade liquid

Thephorin Expectorant

Actifed-C Expectorant

Clistin Expectorant

Tuss-Ornade liquid

Tuss-Ornade Spansules

Benylin Expectorant

Ambenyl Expectorant

Cothera Compound

Pyribenzamine Expectorant

Pyribenzamine Expectorant With Codeine and Ephedrine

However, other products of similar compositions will also be affected even though they are not specifically cited.

The FDA is basing this action on regulations established by the 1962 Harris-Kefauver amendments to the Food, Drug, and Cosmetic Act of 1938 and on the National Academy


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?




Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.